Esther Rajavelu
Stock Analyst at UBS
(0.69)
# 4,068
Out of 5,172 analysts
23
Total ratings
46.15%
Success rate
-22.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Esther Rajavelu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $46 | $70.99 | -35.20% | 4 | Aug 12, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $70 → $32 | $20.17 | +58.65% | 2 | Apr 9, 2024 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $141 → $215 | $312.17 | -31.13% | 5 | Oct 4, 2021 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Sell | $73 | $19.87 | +267.39% | 1 | Aug 19, 2021 | |
| BHVN Biohaven | Downgrades: Neutral | $108 → $109 | $8.93 | +1,120.60% | 6 | Aug 10, 2021 | |
| STOK Stoke Therapeutics | Initiates: Neutral | $35 | $33.51 | +4.45% | 1 | May 18, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $174 → $228 | $180.62 | +26.23% | 1 | Mar 1, 2021 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Perform | n/a | $56.33 | - | 1 | Dec 13, 2019 | |
| INVA Innoviva | Initiates: Hold | $13 | $21.70 | -40.09% | 1 | Nov 20, 2017 | |
| TXMD TherapeuticsMD | Initiates: Buy | $10 | $2.24 | +346.43% | 1 | Jul 21, 2017 |
Ionis Pharmaceuticals
Aug 12, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $70.99
Upside: -35.20%
Denali Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $70 → $32
Current: $20.17
Upside: +58.65%
Alnylam Pharmaceuticals
Oct 4, 2021
Upgrades: Buy
Price Target: $141 → $215
Current: $312.17
Upside: -31.13%
Ultragenyx Pharmaceutical
Aug 19, 2021
Initiates: Sell
Price Target: $73
Current: $19.87
Upside: +267.39%
Biohaven
Aug 10, 2021
Downgrades: Neutral
Price Target: $108 → $109
Current: $8.93
Upside: +1,120.60%
Stoke Therapeutics
May 18, 2021
Initiates: Neutral
Price Target: $35
Current: $33.51
Upside: +4.45%
Jazz Pharmaceuticals
Mar 1, 2021
Maintains: Buy
Price Target: $174 → $228
Current: $180.62
Upside: +26.23%
Arrowhead Pharmaceuticals
Dec 13, 2019
Initiates: Perform
Price Target: n/a
Current: $56.33
Upside: -
Innoviva
Nov 20, 2017
Initiates: Hold
Price Target: $13
Current: $21.70
Upside: -40.09%
TherapeuticsMD
Jul 21, 2017
Initiates: Buy
Price Target: $10
Current: $2.24
Upside: +346.43%